NEULANDLAB - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 4.0
| Stock Code | NEULANDLAB | Market Cap | 21,357 Cr. | Current Price | 16,634 ₹ | High / Low | 19,748 ₹ |
| Stock P/E | 58.8 | Book Value | 1,454 ₹ | Dividend Yield | 0.07 % | ROCE | 26.6 % |
| ROE | 21.5 % | Face Value | 10.0 ₹ | DMA 50 | 15,185 ₹ | DMA 200 | 14,366 ₹ |
| Chg in FII Hold | -0.44 % | Chg in DII Hold | 1.12 % | PAT Qtr | 213 Cr. | PAT Prev Qtr | 40.4 Cr. |
| RSI | 60.5 | MACD | 612 | Volume | 67,144 | Avg Vol 1Wk | 52,053 |
| Low price | 11,011 ₹ | High price | 19,748 ₹ | PEG Ratio | 1.94 | Debt to equity | 0.16 |
| 52w Index | 64.4 % | Qtr Profit Var | 666 % | EPS | 283 ₹ | Industry PE | 30.5 |
📊 Financials: The company demonstrates strong profitability with ROE at 21.5% and ROCE at 26.6%, reflecting efficient capital usage. Debt-to-equity is low at 0.16, showing a healthy balance sheet. Quarterly PAT surged from ₹40.4 Cr. to ₹213 Cr., a massive 666% variation, highlighting exceptional earnings momentum. EPS of ₹283 supports robust cash flow generation.
💹 Valuation: Current P/E of 58.8 is significantly higher than the industry average of 30.5, suggesting overvaluation. The PEG ratio of 1.94 indicates growth prospects are moderately aligned with price. Book value of ₹1,454 against a market price of ₹16,634 implies a stretched P/B ratio. Intrinsic value appears lower than current levels, requiring caution despite strong fundamentals.
🏭 Business Model: The company operates in pharmaceuticals and APIs, benefiting from strong global demand and niche product offerings. Competitive advantage lies in specialized manufacturing, R&D capabilities, and export opportunities. Strong operational performance supports long-term growth, though valuations remain stretched.
📈 Entry Zone: A favorable entry would be closer to ₹15,200–15,500, near the 50 DMA of ₹15,185 and 200 DMA of ₹14,366. Current price of ₹16,634 is above fair value, so accumulation on dips is recommended.
⏳ Long-Term Holding: Strong fundamentals, niche positioning, and global demand support long-term holding. However, stretched valuations and reliance on consistent earnings growth suggest cautious accumulation rather than aggressive buying.
Positive
- ✅ Strong ROE (21.5%) and ROCE (26.6%)
- ✅ Low debt-to-equity ratio (0.16)
- ✅ EPS of ₹283 supports strong cash flow generation
- ✅ PAT growth from ₹40.4 Cr. to ₹213 Cr. shows exceptional earnings momentum
- ✅ Increase in DII holding (+1.12%) shows domestic institutional confidence
Limitation
- ⚠️ Very high P/E (58.8) compared to industry average
- ⚠️ Stretched P/B ratio (Price ₹16,634 vs. Book Value ₹1,454)
- ⚠️ PEG ratio of 1.94 indicates moderate growth prospects
Company Negative News
- 📉 Decline in FII holding (-0.44%) shows reduced foreign investor confidence
Company Positive News
- 📈 PAT growth of 666% quarter-on-quarter highlights operational strength
- 📈 Increase in DII holding (+1.12%) reflects strong domestic institutional support
Industry
- 💊 Pharmaceutical sector benefits from global demand for APIs and specialty drugs
- 📊 Industry P/E at 30.5 suggests peers are valued lower
- 🌍 Growth opportunities in exports, R&D, and niche formulations
Conclusion
Overall, the company is financially strong with excellent return ratios, niche positioning, and exceptional earnings growth. However, valuations are stretched compared to peers, limiting upside potential. Best strategy is cautious accumulation near ₹15,200–15,500 for long-term holding, while avoiding aggressive buying at current levels.
Would you like me to extend this with a peer comparison against other pharmaceutical companies, or a technical analysis view to highlight support/resistance and momentum indicators?